NanOlogy is in development of investigational drugs enabled by its proprietary particle engineering technology which forms patented large surface area microparticles (LSAMs) of pure drug. Designed for local delivery, NanOlogy LSAMs remain at the disease site releasing molecular drug for weeks with gradual subtoxic clearance.
Clinical results across multiple solid tumors support therapeutic potential in both local and metastatic disease based on sustained tumoricidal response, favorable immunomodulatory effect, and minimal systemic toxicity.
Latest NanOlogy News
-
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the IASLC North America Conference on Lung CancerNovember 20, 2023 -
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the 38th SITC Annual MeetingOctober 23, 2023 -
Interim Results from a NanOlogy Phase 2 Clinical Trial of its Intratumoral Investigational Drug in the Treatment of Locally Advanced Pancreatic CancerOctober 10, 2023 -
Pancreas: Response of Locally Advanced Pancreatic Cancer to Intratumoral Injection of Large Surface Area Microparticle Paclitaxel - Initial Report of Safety and Clinical OutcomeOctober 5, 2023 -
AACR Pancreatic Cancer 2023 Poster: EUS-guided Local Administration of Large Surface Area Microparticle Paclitaxel with Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cncer: A Single Center ExperienceOctober 5, 2023 -
AACR Pancreatic Cancer 2023 Poster: Enhancing the Immune Response in Locally Advanced Pancreatic Cancer (LAPC) with Intratumoral Endoscopic Ultrasound-guided Fine Needle Injection of Large Surface Area Microparticle Paclitaxel (LSAM-PTX)October 5, 2023 -
NanOlogy Announces Two Abstracts Have Been Accepted for Presentation at AACR Special Conference in Cancer Research: Pancreatic CancerSeptember 12, 2023 -
NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational DrugsJune 7, 2023
